Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CKPTNASDAQ:DYNNASDAQ:ETNBNASDAQ:OCUL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCKPTCheckpoint Therapeutics$4.16+0.1%$3.86$1.47▼$4.50$348.04M1.182.17 million shs702,832 shsDYNDyne Therapeutics$9.43-5.9%$10.48$6.36▼$47.45$1.07B1.192.35 million shs3.72 million shsETNB89bio$7.58-2.2%$7.33$4.16▼$11.84$1.11B1.231.35 million shs675,618 shsOCULOcular Therapeutix$7.12-0.9%$7.42$4.79▼$11.78$1.13B1.511.43 million shs1.01 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCKPTCheckpoint Therapeutics-0.12%+1.10%+3.37%+11.13%+154.29%DYNDyne Therapeutics-14.88%-14.08%+21.62%-35.78%-61.64%ETNB89bio-9.99%+2.65%+34.32%-33.53%-19.19%OCULOcular Therapeutix-7.12%-12.55%+12.89%-11.69%+23.79%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCKPTCheckpoint Therapeutics2.2394 of 5 stars1.24.00.04.22.10.80.0DYNDyne Therapeutics3.3683 of 5 stars4.51.00.00.03.54.20.0ETNB89bio2.982 of 5 stars4.51.00.00.04.00.80.6OCULOcular Therapeutix3.3788 of 5 stars3.41.00.04.12.41.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCKPTCheckpoint Therapeutics 2.33Hold$4.334.29% UpsideDYNDyne Therapeutics 3.07Buy$47.46403.57% UpsideETNB89bio 3.00Buy$27.25259.36% UpsideOCULOcular Therapeutix 2.89Moderate Buy$16.25128.39% UpsideCurrent Analyst Ratings BreakdownLatest CKPT, DYN, ETNB, and OCUL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2025OCULOcular TherapeutixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $14.004/30/2025ETNB89bioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/24/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)4/8/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)4/8/2025OCULOcular TherapeutixWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform4/8/2025OCULOcular TherapeutixNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/31/2025CKPTCheckpoint TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.80 ➝ $4.803/22/2025ETNB89bioWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)3/21/2025DYNDyne TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$18.00 ➝ $17.003/18/2025OCULOcular TherapeutixRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$17.003/17/2025DYNDyne TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.00 ➝ $46.00(Data available from 5/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCKPTCheckpoint Therapeutics$41K8,488.77N/AN/A($0.47) per share-8.84DYNDyne TherapeuticsN/AN/AN/AN/A$1.49 per shareN/AETNB89bioN/AN/AN/AN/A$5.75 per shareN/AOCULOcular Therapeutix$63.72M17.79N/AN/A$0.79 per share9.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCKPTCheckpoint Therapeutics-$51.85M-$1.43N/A∞N/AN/AN/A-659.07%5/9/2025 (Estimated)DYNDyne Therapeutics-$235.94M-$3.35N/AN/AN/AN/A-57.46%-51.62%N/AETNB89bio-$142.19M-$3.38N/AN/AN/AN/A-59.58%-52.21%5/8/2025 (Estimated)OCULOcular Therapeutix-$80.74M-$1.26N/AN/AN/A-283.74%-45.18%-30.87%N/ALatest CKPT, DYN, ETNB, and OCUL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025CKPTCheckpoint Therapeutics-$0.10N/AN/AN/AN/AN/A5/1/2025Q1 2025ETNB89bio-$0.50-$0.49+$0.01-$0.49N/AN/A3/28/2025Q4 2024CKPTCheckpoint Therapeutics-$0.22-$0.69-$0.47-$0.69N/A$0.04 million3/6/2025Q4 2024ETNB89bio-$0.60-$1.02-$0.42-$1.02N/AN/A3/4/2025Q4 2024DYNDyne Therapeutics-$0.92-$0.88+$0.04-$0.88N/AN/A3/3/2025Q4 2024OCULOcular Therapeutix-$0.24-$0.29-$0.05-$0.29$16.89 million$17.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCKPTCheckpoint TherapeuticsN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/AETNB89bioN/AN/AN/AN/AN/AOCULOcular TherapeutixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCKPTCheckpoint TherapeuticsN/A0.290.29DYNDyne TherapeuticsN/A17.0217.02ETNB89bio0.0911.6611.66OCULOcular Therapeutix0.1913.0112.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCKPTCheckpoint Therapeutics22.00%DYNDyne Therapeutics96.68%ETNB89bioN/AOCULOcular Therapeutix59.21%Insider OwnershipCompanyInsider OwnershipCKPTCheckpoint Therapeutics2.10%DYNDyne Therapeutics20.77%ETNB89bio2.80%OCULOcular Therapeutix3.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCKPTCheckpoint Therapeutics1083.76 million47.81 millionOptionableDYNDyne Therapeutics100113.63 million80.63 millionOptionableETNB89bio40145.98 million103.15 millionOptionableOCULOcular Therapeutix230159.29 million151.71 millionOptionableCKPT, DYN, ETNB, and OCUL HeadlinesRecent News About These CompaniesOcular Therapeutix (NASDAQ:OCUL) Shares Gap Down - What's Next?May 7 at 12:27 PM | marketbeat.comVIDEO: OTX-TKI reduces intraretinal fluid over 1 year with single injectionMay 7 at 11:33 AM | healio.comAnalysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS NumbersMay 7 at 11:33 AM | finance.yahoo.comOcular Therapeutix (NASDAQ:OCUL) Announces Quarterly Earnings ResultsMay 7 at 8:12 AM | marketbeat.comAptus Capital Advisors LLC Has $2.90 Million Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)May 7 at 5:14 AM | marketbeat.comPrice T Rowe Associates Inc. MD Has $5.46 Million Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)May 7 at 4:08 AM | marketbeat.comOcular Therapeutix First Quarter 2025 Earnings: Misses ExpectationsMay 6 at 8:54 AM | finance.yahoo.com1OCUL : Analyst Expectations For Ocular Therapeutix's FutureMay 6 at 8:54 AM | benzinga.comWhy Ocular Therapeutix, Inc.’s (OCUL) Stock Is Down 9.09%May 5 at 9:07 PM | aaii.comOcular Therapeutix Stock Falls as 1Q Misses Targets, R&D Expenses DoubleMay 5 at 4:05 PM | marketwatch.comOcular Therapeutix stock tumbles as Q1 results miss estimatesMay 5 at 11:04 AM | au.investing.comOcular Therapeutix™ Reports First Quarter 2025 Results and Business HighlightsMay 5 at 11:04 AM | finance.yahoo.comOcular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue EstimatesMay 5 at 9:15 AM | zacks.comVoya Investment Management LLC Has $3.17 Million Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)May 5 at 4:23 AM | marketbeat.comWells Fargo & Company MN Has $634,000 Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)May 5 at 3:15 AM | marketbeat.comAcuta Capital Partners LLC Has $9.49 Million Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)May 4 at 7:11 AM | marketbeat.comRaymond James Financial Inc. Takes Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)May 4 at 3:28 AM | marketbeat.comOcular Therapeutix Inc (OCUL) Q1 2025: Everything You Need To Know Ahead Of EarningsMay 3, 2025 | finance.yahoo.comOcular Therapeutix (OCUL) Projected to Post Quarterly Earnings on MondayMay 3, 2025 | americanbankingnews.comOcular Therapeutix Q1 2025 Earnings PreviewMay 2, 2025 | msn.comBarclays PLC Reduces Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)May 2, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Is McDonald’s Stock Serving a Value Meal to Investors? By Jeffrey Neal Johnson | April 13, 2025View Is McDonald’s Stock Serving a Value Meal to Investors? Medtronic: A Dividend Aristocrat With Stability and InnovationBy Jeffrey Neal Johnson | April 22, 2025View Medtronic: A Dividend Aristocrat With Stability and InnovationWingstop Stock Jumps on Q1 Beat, Expansion OutlookBy Jeffrey Neal Johnson | May 4, 2025View Wingstop Stock Jumps on Q1 Beat, Expansion OutlookCKPT, DYN, ETNB, and OCUL Company DescriptionsCheckpoint Therapeutics NASDAQ:CKPT$4.16 +0.01 (+0.12%) As of 03:20 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors. It is developing Olafertinib, which is in Phase 3 clinical trials for the treatment of adult patients with metastatic non-small cell lung cancer; CK-103 for the treatment of various advanced and metastatic solid tumor cancers; and Anti-Carbonic Anhydrase IX (CAIX) antibody, a product candidate in preclinical trials to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has licensing and collaboration agreements with Adimab, LLC for the development of Cosibelimab; NeuPharma, Inc., to develop and commercialize Olafertinib; and Jubilant Biosys Limited for the development and commercialization of novel compounds that inhibit BET bromodomains. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.Dyne Therapeutics NASDAQ:DYN$9.43 -0.60 (-5.94%) As of 03:19 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.89bio NASDAQ:ETNB$7.58 -0.17 (-2.15%) As of 03:20 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Ocular Therapeutix NASDAQ:OCUL$7.12 -0.07 (-0.91%) As of 03:20 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Disney Stock Jumps on Earnings—Is the Magic Sustainable? AMD Relieves Market Despite Ongoing Share Price Outlook Caution Gold’s Record Run in 2025: Here Are 3 Ways to Ride the Surge What the New Quarter Says About Super Micro Computer's Future Archer Stock Eyes Q1 Earnings After UAE Updates Ford Motor Stock Rises After Earnings, But Momentum May Not Last Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx Boost Lemonade Delivers Sweet Results, Price Reversal to Accelerate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
